Konrad, "Atorvastatin increases human serum levels of proprotein convertase
subtilisin/kexin type 9," Journal of Lipid Research, vol.
Binding of proprotein convertase
subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation.
GP-C was posttranscriptionally processed by S1P (the cellular proprotein convertase
site 1 protease) to yield the glycoproteins, and the consensus motif R-(R/K/ H)-L-(A/L/S/T/F) was identified as the S1P recognition site of Luna virus glycoprotein (11,12).
Partial Purification and Characterization of Secreted Proprotein Convertase
Furin and PACE4.
According to the companies, Praluent is the only PCSK9 (proprotein convertase
subtilisin/kexin type 9) inhibitor available in two starting doses as a single 1 millilitre (ml) injection (75 mg and 150 mg) once every two weeks and can also be administered as 300 mg once every four weeks (monthly).
TUESDAY, April 3, 2018 (HealthDay News) -- Outcomes-based pricing does not reduce the costs of proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine.
Another study presented, "Predicting Cardiovascular Risk Using Common Utilization Management Criteria for Proprotein Convertase
Subtilisin/Kexin Type 9 Inhibitors in Commercially Insured Patients With Atherosclerotic Cardiovascular Disease," showed commercial payer utilization management criteria fail to prioritize patients at the highest risk for CV events.
Insurance approval rates for pro-protein convertase
subtilisin / kexin type 9 inhibitors are strikingly low, according to a study published in Circulation.
FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) was eagerly anticipated as the first dedicated cardiovascular outcomes trial to report results for a proprotein convertase
subtilisin/kexin type 9 inhibitor, the novel drug class that achieves previously unattainable LDL lowering.
Within the field of lipid metabolism, the rapid clinical development of proprotein convertase
subtilisin kexin type 9 (PCSK9) inhibitors to reduce LDL cholesterol provides proof-of-concept for the potential of this approach.
(1) Mutations in the low density lipoprotein receptor (LDLR), apolipoprotein B (including Ag(x) antigen) (APOB), and proprotein convertase
subtilisin/kexin 9 (PCSK9) genes are linked with FH1, FH2 and FH3, respectively.